FibroBiologics Inc (FBLG) USD0.00001

Sell:$1.12Buy:$1.13$0.12 (9.27%)

Prices delayed by at least 15 minutes
Sell:$1.12
Buy:$1.13
Change:$0.12 (9.27%)
Prices delayed by at least 15 minutes
Sell:$1.12
Buy:$1.13
Change:$0.12 (9.27%)
Prices delayed by at least 15 minutes

Company Information

About this company

FibroBiologics, Inc. is a cell therapy regenerative medicine company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The Company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat Multiple sclerosis (MS) and has completed the Phase I study. The Company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing.

Key people

Pete Oheeron
Chairman of the Board, Chief Executive Officer, Founder
Robert E. Hoffman
Chief Financial Officer, Director
Hamid Khoja
Chief Scientific Officer
Richard Cilento
Independent Director
Stacy Coen
Independent Director
Matthew Link
Independent Director
Victoria Niklas
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US31573L1052
  • Market cap
    $40.49m
  • Employees
    10
  • Shares in issue
    35.20m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.